The ovaries are not the problem. They are the symptom.
Durante décadas, millones de mujeres han cargado con un diagnóstico cuyo nombre apuntaba al síntoma visible y no a la causa profunda. La medicina internacional, impulsada por revistas como The Lancet, se prepara para corregir ese error: en 2028, el síndrome de ovario poliquístico pasará a llamarse Síndrome Poliendocrino Ovárico Metabólico, reconociendo que lo que ocurre en los ovarios es consecuencia de una alteración hormonal y metabólica sistémica. Cambiar el nombre es, en el fondo, cambiar la pregunta que la medicina le hace al cuerpo de la mujer.
- El nombre actual ha llevado a pacientes y médicos a tratar una enfermedad sistémica como si fuera un problema localizado en los ovarios, postergando intervenciones que podrían prevenir infartos y accidentes cerebrovasculares.
- La resistencia a la insulina, el exceso de hormonas masculinas y el hígado graso forman una tormenta metabólica que avanza en silencio mientras el diagnóstico sigue centrado en los quistes.
- Especialistas como el Dr. Roger González en Talca ya trabajan bajo el nuevo paradigma: el riesgo real no es la infertilidad, sino la hipertensión, la dislipidemia y el síndrome metabólico que se acumulan con los años.
- The Lancet y el consenso médico internacional empujan para que en 2028 el nuevo nombre —SPOM— redefina los protocolos de diagnóstico, tratamiento y educación de las pacientes.
- La transición terminológica abre la posibilidad de que la conversación clínica deje de girar en torno a la maternidad y comience a abordar la salud cardiovascular y metabólica a largo plazo.
En Talca, un ginecólogo observa cómo la medicina internacional comienza a ponerse al día con lo que la enfermedad realmente es. Durante décadas, el síndrome de ovario poliquístico fue nombrado por el detalle más visible —los quistes— y ese detalle se convirtió en toda la historia. Pero los ovarios no son el origen del problema: son su expresión.
El Dr. Roger González, obstetra-ginecólogo en Andes Salud Talca, forma parte de una conversación que ha llegado a un punto de inflexión. The Lancet impulsa un cambio de nombre que será oficial en 2028: la condición pasará a llamarse Síndrome Poliendocrino Ovárico Metabólico —SPOM—. Cada palabra del nuevo nombre describe algo real: la cascada hormonal que eleva los andrógenos y genera acné e hirsutismo, la resistencia a la insulina que el cuerpo no logra regular, el hígado que acumula grasa. Los ovarios fallan, sí, pero porque el entorno metabólico que los rodea se ha desestabilizado.
El nombre importa porque moldea la forma en que los médicos piensan y en que las pacientes entienden su propio cuerpo. Una mujer diagnosticada con síndrome de ovario poliquístico puede creer razonablemente que su problema es localizado, algo que atender solo si desea embarazarse. Lo que no ve es la acumulación silenciosa de riesgo: hipertensión, colesterol elevado, posibilidad de un infarto o un accidente cerebrovascular en la mediana edad, síndrome metabólico como antesala de la diabetes tipo 2.
González es directo sobre lo que está en juego: las consecuencias de un SPOM mal tratado van mucho más allá del ovario, y no llegan como sorpresa tardía, sino como la trayectoria natural de una enfermedad que no fue abordada en su verdadera dimensión. El cambio de nombre es una invitación a que la medicina prevenga esa cascada antes de que se vuelva irreversible, desplazando la pregunta clínica desde '¿quiere tener hijos?' hacia '¿entiende lo que su cuerpo necesita?'. El mundo médico ya se está moviendo; la pregunta es si la terminología arrastrará consigo la práctica.
A gynecologist in Talca is watching the medical establishment finally catch up to what the disease actually is. For decades, polycystic ovary syndrome has been named for the cysts that appear on the ovaries—a detail so obvious it became the whole story. But the ovaries are not the problem. They are the symptom.
Dr. Roger González, an obstetrician-gynecologist at Andes Salud Talca, is part of an international conversation that has reached a turning point. The Lancet, one of the world's most respected medical journals, has begun pushing for a name change. By 2028, when a new medical consensus is formally adopted, the condition will be called Síndrome Poliendocrino Ovárico Metabólico—SPOM in Spanish, or Metabolic Polyendocrine Ovarian Syndrome in English. It is a small change in nomenclature that reflects something much larger: a fundamental shift in how medicine understands what is happening inside the bodies of millions of women.
The new name breaks the disease into its actual components. "Poliendocrino"—polyendocrine—describes the cascade of hormonal disruption: elevated male hormones that cause acne and excess facial hair, insulin resistance that the body cannot regulate, a liver accumulating fat it should not store. "Ovárico" acknowledges that yes, the ovaries malfunction, but only because the environment surrounding them has gone wrong. "Metabólico" names the real threat. This is not primarily a fertility problem, though infertility is often how women first discover they have it. This is a metabolic crisis.
Why does the name matter? Because names shape how doctors think and how patients understand their own bodies. A woman told she has polycystic ovary syndrome may reasonably believe her problem is localized, contained, something to address if she wants to become pregnant. She may not understand that if she leaves this condition untreated or poorly managed, she is accumulating risk. High blood pressure. Elevated cholesterol. The possibility of a heart attack or stroke in middle age. Metabolic syndrome—the constellation of conditions that precedes type 2 diabetes and cardiovascular disease.
González is clear about what is at stake. The long-term consequences of untreated or inadequately managed PCOS extend far beyond the ovary. Women with this condition face systemic threats: hypertension, dyslipidemia, myocardial infarction, cerebrovascular accident, metabolic syndrome. These are not complications that emerge decades later as a surprise. They are the natural trajectory of the underlying disorder if it is not addressed comprehensively.
The renaming is not merely semantic. It is an invitation to medicine to think differently about prevention and treatment. If PCOS is understood as a metabolic disorder first and an ovarian disorder second, then the approach changes. Screening changes. Patient education changes. The conversation a doctor has with a woman in her twenties shifts from "Do you want to have children?" to "Do you understand what your body is doing and what it needs?" It becomes possible to prevent the cascade before it becomes irreversible.
The transition will be official in 2028. Until then, the old name persists in clinical practice, in patient conversations, in the collective understanding of what this disease is. But the medical world is already moving. The question now is whether the shift in terminology will translate into a shift in how women are diagnosed, treated, and counseled about their futures.
Citações Notáveis
If a patient continues with this syndrome without treatment or with poor management, long-term exposure leads to severe systemic consequences including hypertension, high cholesterol, heart attacks, strokes, and metabolic syndrome.— Dr. Roger González, obstetrician-gynecologist at Andes Salud Talca
A Conversa do Hearth Outra perspectiva sobre a história
Why does renaming a disease matter if the treatment stays the same?
Because the name shapes what doctors look for and what patients think they're being treated for. If you call it an ovary problem, you miss the metabolic crisis happening everywhere else in the body.
So women have been misunderstanding their own diagnosis?
Not misunderstanding exactly. More like seeing only one piece of a much larger picture. A woman might think, "I have trouble getting pregnant," when the real story is "My body cannot regulate insulin, and I'm building toward a heart attack."
How many women are we talking about?
PCOS affects somewhere between 8 and 20 percent of women of reproductive age, depending on which diagnostic criteria you use. It's one of the most common endocrine disorders in women, and most of them don't know the full scope of what they're managing.
What changes when the name officially shifts in 2028?
Screening protocols change. Medical education changes. A gynecologist will start asking different questions and ordering different tests. A woman will hear a different explanation of what her body needs from her.
Is this a problem that's been ignored, or just misnamed?
Both. The disease itself has been there all along. But by naming it after the ovary, medicine focused on one symptom and missed the systemic threat underneath. That's not malice—it's just how medicine works sometimes. You see what you're looking for.